CSL Behring is investing approximately 610 million euros in new production capacity in Marburg through 2031

Economic Affairs Minister Kaweh Mansoori welcomes the major investment as a strong commitment to Hesse as an industrial hub

20-Nov-2026
AI-generated image

Illustrative image

The international biotechnology company CSL Behring is investing approximately 610 million euros by 2031 to expand its production capacity in Marburg. The company presented its investment plans at the “Marburg 2030” event. Plans include, among other things, two new filling lines with eight freeze-drying systems, as well as a new production facility for fibrinogen, a vital active ingredient used to treat severe bleeding.

Hesse’s Minister of Economic Affairs and Deputy Minister-President Kaweh Mansoori welcomed the decision as an important commitment to Hesse as an industrial hub: “Anyone who relies on a vital medication must be able to count on its availability. To achieve this, we need strong pharmaceutical production in Germany and Europe. The investment of 610 million euros secures important production capacities and strengthens highly skilled jobs here in Hesse. It demonstrates that Hesse has the companies, the skilled workforce, and the research strength to succeed in international competition. As the state government, we ensure reliable framework conditions and streamlined procedures. We bring business and science together so that research and good ideas can lead to new products and secure jobs in Hesse.”

“CSL Behring’s investment demonstrates great confidence in the sustainability and competitiveness of this location. The Marburg Pharmaceutical and Life Sciences Park offers a reliable and modern infrastructure and ideal conditions for growth and innovation. Added to this is a unique network of business, science, and government that stands for partnership, progress, and reliability. The Marburg location offers the stable framework conditions on the ground that are all the more important in times of global uncertainty,” said Marburg’s Mayor Dr. Thomas Spies.

Dr. Niklas Schier, Site Manager at CSL Behring, added: “Every dose that leaves Marburg is intended for a patient who depends on it. A reliable supply requires continuous investment in plasma collection and production, as well as a resilient global supply network. This responsibility drives our teams every day and demonstrates why this investment is so important to us. With ‘Marburg 2030,’ we are building the future of the site—for our employees, for the region, and for patients worldwide.”

The investment strengthens Marburg as a major European pharmaceutical hub, secures highly specialized production expertise in Hesse, and contributes to the security of supply for essential medicines in Germany and Europe.

Expansion of Production Capacity in Hesse

With this investment, CSL Behring is expanding its capacity to manufacture medicines derived from human blood plasma. These products are used in particular to treat rare, chronic, and severe diseases. With the new production facility for fibrinogen, the company is also expanding the manufacture of a medication used to treat life-threatening bleeding, such as after accidents, surgeries, or childbirth. State-of-the-art automation and digital process control technologies are intended to further advance production processes and ensure a reliable long-term supply of medicines.

Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.

Other news from the department business & finance

Most read news

More news from our other portals